Form 4: uniQure N.V. Chief Legal Officer Reports Acquisition and Disposal of Shares and Stock Options

Jeannette Potts, Chief Legal Officer of uniQure N.V., reports the acquisition of restricted share units and stock options, as well as the disposal of ordinary shares.

Summary

• On March 1, 2024, Jeannette Potts, the Chief Legal Officer of uniQure N.V., reported transactions involving the company's securities.
• Potts acquired 49,500 restricted share units under the Issuer's 2014 Share Incentive Plan, each representing the right to receive one Ordinary Share.
• She also acquired 85,500 stock options with an exercise price of $5.59, exercisable starting March 1, 2025, and expiring on March 1, 2034.
• Additionally, Potts disposed of 96,600 ordinary shares.
• Following these transactions, Potts directly owns 85,500 derivative securities and 96,600 ordinary shares.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing insider transactions. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Positives

• The grant of restricted share units and stock options to the Chief Legal Officer aligns her interests with the long-term success of the company.
• The vesting schedules for the restricted share units and stock options incentivize continued service with the company.

Negatives

• The disposal of 96,600 ordinary shares by the Chief Legal Officer could be perceived negatively by investors, although the reason for disposal is not disclosed.

Risks

• The value of the stock options is dependent on the future performance of uniQure N.V.'s stock price.
• The vesting of the restricted share units and stock options is contingent upon the Reporting Person's continued relationship with the Issuer.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company executives regarding their holdings of company stock and related derivatives.

Comparison to Industry Standards

• Insider trading disclosures are standard practice for publicly listed companies like uniQure N.V.
• Companies like BioMarin Pharmaceutical Inc. and Vertex Pharmaceuticals Incorporated also have similar insider trading disclosures.
• The vesting schedules for stock options and restricted share units are typical for executive compensation packages in the biotechnology industry.

Stakeholder Impact

• The transactions may influence investor perception of the company, depending on how they interpret the insider's actions.
• The vesting schedules for the restricted share units and stock options incentivize the Chief Legal Officer to remain with the company, which benefits employees and shareholders.

Key Dates